PT  - JOURNAL ARTICLE
AU  - Mai Nguyen, Thi Ngoc
AU  - Chen, Li-Ju
AU  - Trares, Kira
AU  - Stocker, Hannah
AU  - Holleczek, Bernd
AU  - Beyreuther, Konrad
AU  - Brenner, Hermann
AU  - Schöttker, Ben
TI  - Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies
AID  - 10.1101/2021.09.20.21263830
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.20.21263830
4099  - http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263830.short
4100  - http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263830.full
AB  - Objectives To investigate the association between long term low-dose acetylsalicylic acid (LDASA) use and the development of all-cause dementia, Alzheimer’s disease (AD) and vascular dementia (VD).Design Meta-analysis of individual participant data from two prospective cohort studies.Setting Community-dwelling older adults from Germany (ESTHER) and United Kingdom (UK Biobank).Participants 5,258 ESTHER and 305,394 UK Biobank participants who were 55 years or older and completed drug assessment were included for analysis.Main outcome measures Cox regression models with inverse probability of treatment weighting to model the underlying cardiovascular risk were used to assess the associations of LDASA use with all-cause dementia, AD and VD incidence.Results 476 cases of all-cause dementia, 157 cases of AD and 183 cases of VD were diagnosed over a median of 14.3 years of follow-up in ESTHER. In the UK Biobank, 5,584 participants were diagnosed with all-cause dementia, 2,029 with AD and 1,437 with VD over a median of 11.6 years. The meta-analysis of both cohorts revealed a weak reduction in hazards for all-cause dementia (HR [95% CI]: 0.96 [0.93 to 0.99]). The strongest protective effect of LDASA was observed in participants with coronary heart disease (CHD) in both cohorts, and a significant interaction was detected. In particular, in meta-analysis, a 31% reduction in hazard for AD, 69% for VD and 34% for all-cause dementia were observed (HR [95% CI]: 0.69 [0.59 to 0.80], 0.31 [0.27 to 0.35], 0.46 [0.42 to 0.50], respectively). Furthermore, compared to non-users, users of LDASA for 10 years or longer (who likely use it because they have CHD or a related diagnosis putting them at an increased risk for cardiovascular events) demonstrated a strong protective effect on all dementia outcomes, especially for VD (HR [95% CI]: 0.48 [0.42 to 0.56]) whereas no protective associations were observed with shorter LDASA use.Conclusions The protective potential of LDASA for all-cause dementia, AD and VD seems to strongly depend on pre-existing CHD and the willingness of patients to take it for a minimum of ten years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData collection of the ESTHER study follow-up used for this project was supported by the Federal Ministry of Education and Research (Berlin, Germany) (grant numbers 01ET0717 and 01GY1320A) and the Saarland Ministry for Social Affairs, Health, Women, and Family Affairs. UK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. The sponsors had no role in data acquisition or the decision to publish the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ESTHER was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg and Medical Association of Saarland (Application number: 58/2000). UK Biobank received ethical approval from the North West Multicentre Research Ethics Committee (REC reference: 11/NW/03820). Both ESTHER and UK Biobank are conducted in accordance with the 1964 Helsinki declaration and its later amendments.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from ESTHER is available upon reasonable request that is compatible with participants' informed consent. Data from the UK Biobank (https://www.ukbiobank.ac.uk/) is available to bona fide researchers on application. Part of this reseach was conducted using the UK Biobank Resource under application 69578.